Using leftover patient samples for clinical research on blood diseases
The Use of Residual De-identified Specimens and/or Samples From Patients for Clinical Research
This study is trying to use leftover blood and tissue samples from patients to help learn more about blood diseases.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 2000 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Invivoscribe, Inc. Industry-sponsored |
| Locations | 1 site (San Diego, California) |
| Trial ID | NCT06222164 on ClinicalTrials.gov |
What this trial studies
This observational study focuses on collecting residual human specimens and samples from patients whose samples have been sent for testing at LabPMM, LLC. The study aims to acquire various types of specimens, including peripheral blood, bone marrow, genomic DNA, and formalin-fixed paraffin-embedded tissue. These samples will be utilized for clinical research purposes either at LabPMM or partner institutions, contributing to the understanding of hematologic diseases.
Who should consider this trial
Good fit: Ideal candidates for this study are patients aged 18 years and older whose specimens have been sent to LabPMM for clinical testing.
Not a fit: Patients whose samples have been obtained from third-party vendors or previously enrolled in clinical studies may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could enhance the understanding and treatment of hematologic diseases by utilizing existing patient samples.
How similar studies have performed: Other studies utilizing residual specimens for research have shown promise, indicating that this approach is both valid and beneficial.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. Specimen/sample, peripheral blood (PB), bone marrow (BM), genomic DNA (gDNA) and/or formalin-fixed paraffin-embedded tissue (FFPE) from patients whose specimens/samples have been sent to LabPMM for clinical testing 2. Donor Age ≥ 18 years Exclusion Criteria: 1. Sample/specimen has been obtained from a third-party vendor with a Materials Transfer Agreement (MTA) on file with LabPMM 2. The specimens/samples have previously been enrolled in a clinical study
Where this trial is running
San Diego, California
- LabPMM — San Diego, California, United States (Recruiting)
Study contacts
- Study coordinator: Andrew Schut
- Email: aschut@invivoscribe.com
- Phone: +1 858.224.6600
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.